Journal of the National Cancer Center最新文献

{"title":"A global perspective on the ethnic-specific BRCA variation and its implication in clinical application","authors":"San Ming Wang","doi":"10.1016/j.jncc.2022.12.001","DOIUrl":"10.1016/j.jncc.2022.12.001","url":null,"abstract":"<div><p>Pathogenic <em>BRCA1</em> and <em>BRCA2</em> (<em>BRCA</em>) variation is the genetic predisposition for high cancer risk affecting mostly breast and ovarian. <em>BRCA</em> variation information is widely used in clinical diagnosis, treatment, and prevention of <em>BRCA</em>-related cancer. The positive selection imposed on human <em>BRCA</em> leads to highly ethnic-specific <em>BRCA</em> variation to adapt different living environment on earth. Most of the human <em>BRCA</em> variants identified so far were from the European descendant populations and used as the standard reference for global human populations, whereas <em>BRCA</em> variation in other ethnic populations remains poorly characterized. This review addresses the origin of ethnic-specific <em>BRCA</em> variation, the importance of ethnic-specific <em>BRCA</em> variation in clinical application, the limitation of current <em>BRCA</em> variation data, and potential solutions to fill the gap.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 14-20"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46801888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The NCC mathematical modeling framework for decision-making of six major cancers","authors":"Changfa Xia,&nbsp;Wanqing Chen","doi":"10.1016/j.jncc.2022.11.002","DOIUrl":"10.1016/j.jncc.2022.11.002","url":null,"abstract":"<div><h3>Objective</h3><p>Mathematical modeling and simulation is a useful research method to inform decision-making. This article aims to describe the National Cancer Center (NCC) modeling framework and how well it reproduces observed empirical data for six major cancers.</p></div><div><h3>Methods</h3><p>We developed the NCC modeling framework for six major cancers in China (lung, liver, stomach, colorectal, esophageal, and breast), which simulates the life-histories represented by states among normal, precancerous lesion, stage-specific invasive cancer, and death for six cancers separately. Each NCC simulation model could be illustrated as an integrated framework of 3 modules: a demography module, natural history module, and screening module. Combined with costs and health utilities data, the models could have many detailed outputs for informing decisions, including the harm of screening (e.g., false positives, complications, and overdiagnosis), healthcare costs, and benefits (quality-adjusted life years gained, cancer incidence and mortality, and investment returns). We calibrated the models to Chinese population-based observations on cancer incidence, mortality, and stage distribution. All models are validated by comparing model simulated results to data observed from nationwide cancer registration and a large prospective cohort study.</p></div><div><h3>Results</h3><p>The simulated results from the calibrated models consistently match the epidemiological patterns in six major cancer incidence, mortality, and stage distributions in China. Model projected age-specific cancer incidence and mortality were close to the observed data in the national cancer registration. The NCC modeling framework reproduced the cumulative cancer cases and deaths observed in the prospective cohort study at 7.0 and 10.8 years of follow-up. Model estimated net survival rates also consistent with population-based statistics.</p></div><div><h3>Conclusion</h3><p>The NCC modeling framework's ability to reproduce the observed population-level cancer statistics and the cancer cases in a prospective cohort study suggests its results are reliable to inform decision-making related to six major cancers in China.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 35-47"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48411519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study","authors":"Nan Bi ,&nbsp;Kunpeng Xu ,&nbsp;Hong Ge ,&nbsp;Ming Chen ,&nbsp;Mingyan E ,&nbsp;Li Zhang ,&nbsp;Jianzhong Cao ,&nbsp;Xu Zhang ,&nbsp;Xiao Ding ,&nbsp;Bing Xia ,&nbsp;Lujun Zhao ,&nbsp;Lijie Han ,&nbsp;Jiancheng Li ,&nbsp;Chen Hu ,&nbsp;Luhua Wang","doi":"10.1016/j.jncc.2022.11.003","DOIUrl":"10.1016/j.jncc.2022.11.003","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the optimal management of patients with epidermal growth factor receptor gene (<em>EGFR</em>) mutant locally advanced non-small cell lung cancer (LA-NSCLC).</p></div><div><h3>Methods</h3><p>Patients with unresectable stage III lung adenocarcinoma (LAC) harboring <em>EGFR</em> mutations from 2012 to 2018 were analyzed retrospectively, and were categorized into three groups according to the primary treatment: chemoradiotherpy (CRT) (group 1), combined radiation therapy (RT) and EGFR-tyrosine kinase inhibitors (TKI) with/without chemotherapy (group 2), and EGFR-TKI alone until tumor progression (group 3). Inverse probability of multiple treatment weighting (IPTW) of propensity score was used to compare overall survival (OS) and progression free survival (PFS) between treatments and account for confounding.</p></div><div><h3>Results</h3><p>A total of 104, 105, and 231 patients were categorized into groups 1, 2, and 3, respectively. After IPTW adjustment, the median PFS for each group was 12.4, 26.2, and 16.2 months (log-rank <em>P &lt;</em> 0.001), and the median OS was 51.0, 67.4 and 49.3 months (log-rank <em>P</em> = 0.084), respectively. Compared with those in group 1, patients in group 2 had significantly improved PFS [adjusted hazard ratio HR (aHR), 0.40; 95% confidence interval (CI): 0.29, 0.54; <em>P &lt;</em> 0.001] and OS (aHR, 0.61; 95% CI: 0.38, 0.98; <em>P</em> <em>=</em> 0.039). Patients in group 3 had prolonged PFS (aHR, 0.66; 95% CI: 0.50, 0.87; <em>P</em> <em>=</em> 0.003), but not OS (aHR, 0.90; 95% CI: 0.62, 1.32; <em>P</em> <em>=</em> 0.595). Doubly robust IPTW analysis and multivariable Cox regression analysis yielded similar findings.</p></div><div><h3>Conclusions</h3><p>EGFR-TKIs after chemoradiation or combined with radiation alone correlated with the longest PFS and OS (versus CRT or TKIs alone) in patients with <em>EGFR</em>-mutant unresectable LA-NSCLC. Well-designed prospective trials were warranted.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 65-71"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46423416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort study.","authors":"Yousheng Mao, Shugeng Gao, Yin Li, Chun Chen, Anlin Hao, Qun Wang, Lijie Tan, Jianqun Ma, Gaoming Xiao, Xiangning Fu, Wentao Fang, Zhigang Li, Yongtao Han, Keneng Chen, Renquan Zhang, Xiaofei Li, Tiehua Rong, Jianhua Fu, Yongyu Liu, Weimin Mao, Meiqing Xu, Shuoyan Liu, Zhentao Yu, Zhirong Zhang, Yan Fang, Donghong Fu, Xudong Wei, Ligong Yuan, Shan Muhammad, Jie He","doi":"10.1016/j.jncc.2023.02.002","DOIUrl":"10.1016/j.jncc.2023.02.002","url":null,"abstract":"<p><strong>Background: </strong>Whether minimally invasive esophagectomy (MIE) is superior to open esophagectomy (OE) in the treatment of esophageal squamous cell carcinoma (ESCC) is still uncertain. Therefore, this multicenter prospective study aimed to compare MIE with OE in postoperative parameters and long-term survival.</p><p><strong>Methods: </strong>All hospitalized patients with cT1b-3N0-1M0 thoracic ESCC treated by MIE or OE were enrolled from 19 selected centers from April 1, 2015 to December 31, 2018. The propensity score matching (PSM) was performed to minimize the selection bias. The basic clinicopathological characteristics and 3-year overall survival (OS) as well as disease-free survival (DFS) of two groups were compared by R version 3.6.2.</p><p><strong>Results: </strong>MIE were performed in 1,387 patients and OE in 335 patients. 335 cases in each group were finally matched by PSM, and no significant differences in the essential demographic characteristics were observed between the MIE and OE groups after PSM. Compared with OE, MIE had significantly less intraoperative bleeding, less total drainage volume, shorter postoperative hospital stay, and harvested significantly more lymph nodes (LNs) (all <i>P</i> < 0.001). There were no significant differences in the major postoperative complications and death rates between MIE and OE. The 3-year OS and DFS were 77.0% and 68.1% in the MIE group versus 69.3% and 60.9% in the OE group (OS: <i>P</i> = 0.03; DFS: <i>P</i> = 0.09), and the rates were 75.1% and 66.5% in the MIE group versus 66.9% and 58.6% in the OE group for stage cII patients (OS: <i>P</i> = 0.04, DFS: <i>P</i> = 0.09), respectively.</p><p><strong>Conclusions: </strong>Compared with OE, MIE is a safe and effective treatment approach with similar mortality and morbidity. It has the advantages in harvesting more LNs, improving postoperative recovery and survival of stage cII ESCC patients.</p>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"1 1","pages":"106-114"},"PeriodicalIF":7.6,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54587073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk assessment of self-sampling HPV tests based on PCR, signal amplification to guide the appropriate screening intervals: A prospective study in China","authors":"Xuelian Zhao ,&nbsp;Shangying Hu ,&nbsp;Shuang Zhao ,&nbsp;Remila Rezhake ,&nbsp;Liuye Huang ,&nbsp;Xianzhi Duan ,&nbsp;Xun Zhang ,&nbsp;Youlin Qiao ,&nbsp;Marc Arbyn ,&nbsp;Fanghui Zhao","doi":"10.1016/j.jncc.2022.08.002","DOIUrl":"10.1016/j.jncc.2022.08.002","url":null,"abstract":"<div><h3>Objective</h3><p>We assessed the longitudinal risk of developing cervical intraepithelial neoplasia (CINs) with self-sampling human papillomavirus (HPV) tests, based on polymerase chain reaction (PCR) and signal amplification (<em>care</em>HPV), to explore the appropriate intervals for cervical cancer screening.</p></div><div><h3>Methods</h3><p>A prospective study was conducted in China during 2017–2020. Participants were invited for PCR and <em>care</em>HPV tests with self-samples at baseline. Women positive in either HPV test underwent colposcopy and biopsy if necessary. Women with baseline CIN grade one (CIN1) or less were followed up over 3 years. The absolute risk was assessed by the immediate risk (IR) and cumulative risk (CR), and the relative risk was assessed by the hazard ratio (HR) with a 95% confidence interval (CI).</p></div><div><h3>Results</h3><p>A total of 8,126 women were included in the final analysis. Women positive for the PCR HPV test had comparable IRs of CIN2+ and CIN3+ to those positive on the <em>care</em>HPV test. With triage by HPV genotyping, women with HPV 16/18 infection had the highest IRs of CIN2+ (21.15%) and CIN3+ (9.67%). For CR, women negative for PCR HPV test had a lower risk of CIN2+ than that reported in women negative on <em>care</em>HPV test (0.57% versus 0.98%, HR = 0.58, 95% CI: 0.38, 0.87), but no significant difference was found in the CRs of CIN3+ between them (0.25% versus 0.39%, HR = 0.64, 95% CI: 0.34, 1.20). Among women with CIN1 or less at baseline, women who were persistent or recurrent positive on <em>care</em>HPV or PCR HPV test had a higher risk of developing CIN3+ (11.36%-14.59%), compared with women remained HPV negative from baseline throughout follow-up (≤0.28%).</p></div><div><h3>Conclusions</h3><p>Routine screening with 3-year intervals is acceptable for self-sampling HPV tests based on PCR or <em>care</em>HPV test. Women positive on HPV16/18 triaging at baseline or with CIN1 or less at baseline while being persistent or recurrent positive on <em>care</em>HPV or PCR HPV test during 3-year follow-up require immediate colposcopy or treatment.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 298-305"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000564/pdfft?md5=6182765ecc8bc681a245c4f1647b6917&pid=1-s2.0-S2667005422000564-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41388616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies","authors":"Jiajun Luo ,&nbsp;Andrew Craver ,&nbsp;Kendall Bahl ,&nbsp;Liz Stepniak ,&nbsp;Kayla Moore ,&nbsp;Jaime King ,&nbsp;Yawei Zhang ,&nbsp;Briseis Aschebrook-Kilfoy","doi":"10.1016/j.jncc.2022.08.003","DOIUrl":"10.1016/j.jncc.2022.08.003","url":null,"abstract":"<div><p>Non-Hodgkin lymphoma (NHL) contributes to significant cancer burden and mortality globally. In recent years, much insight into the causes of NHL has been gained by evaluating global differences through international collaboration and data pooling. NHL comprises different subtypes that are known to behave differently, exhibit different prognoses, and start in distinct cell types (B-cell, T-cell, and NK-cell, predominantly), and there is increasing evidence that NHL subtypes have different etiologies. Classification of NHL can be complex, with varying subtype frequencies, and is a consideration when evaluating geographic differences. Because of this, international pooling of well-executed epidemiologic studies has conferred power to evaluate NHL by subtype and confidence with minimal misclassification. Given the decreasing burden in some regions while cases rise in Asia, and especially China, this report focuses on a review of the established etiology of NHL from the epidemiologic literature in recent decades, highlighting work from China. Topics covered include demographic patterns and genetic determinants including family history of NHL, as well as infection and immunosuppression, lifestyle, environment, and certain occupational exposures contributing to increased disease risk.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 226-234"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000576/pdfft?md5=09e6a1532ee6ef8d691b88fc2a49699a&pid=1-s2.0-S2667005422000576-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54587064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer","authors":"Jiujie Cui ,&nbsp;Feng Jiao ,&nbsp;Qi Li ,&nbsp;Zheng Wang ,&nbsp;Deliang Fu ,&nbsp;Jun Liang ,&nbsp;Houjie Liang ,&nbsp;Tingyi Xia ,&nbsp;Tao Zhang ,&nbsp;Yang Zhang ,&nbsp;Guanghai Dai ,&nbsp;Zhihong Zhang ,&nbsp;Jian Wang ,&nbsp;Yongrui Bai ,&nbsp;Yuxian Bai ,&nbsp;Feng Bi ,&nbsp;Donghui Chen ,&nbsp;Dan Cao ,&nbsp;Jie Chen ,&nbsp;Weijia Fang ,&nbsp;Liwei Wang","doi":"10.1016/j.jncc.2022.08.006","DOIUrl":"10.1016/j.jncc.2022.08.006","url":null,"abstract":"<div><p>Pancreatic cancer is one of the leading causes of cancer-related mortality in both developed and developing countries. The incidence of pancreatic cancer in China accounts for about a quater of the global incidence, and the epidemiological characteristics and therapeutic strategies differ due to social, economic, cultural, environmental, and public health factors. Non-domestic guidelines do not reflect the clinicopathologic characteristics and treatment patterns of Chinese patients. Thus, in 2018, the Chinese Society of Clinical Oncology (CSCO) organized a panel of senior experts from all sub-specialties within the field of pancreatic oncology to compile the Chinese guidelines for the diagnosis and treatment of pancreatic cancer. The guidelines were made based on both the Western and Eastern clinical evidence and updated every one or two years. The experts made consensus judgments and classified evidence-based recommendations into various grades according to the regional differences, the accessibility of diagnostic and treatment resources, and health economic indexes in China. Here we present the latest version of the guidelines, which covers the diagnosis, treatment, and follow-up of pancreatic cancer. The guidelines might standardize the diagnosis and treatment of pancreatic cancer in China and will encourage oncologists to design and conduct more clinical trials about pancreatic cancer.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 205-215"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000618/pdfft?md5=8d4dd4ccda7edef3a8cf88afb5f15815&pid=1-s2.0-S2667005422000618-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47751659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiology of lung cancer: Evidence from epidemiologic studies","authors":"Kaiyong Zou ,&nbsp;Peiyuan Sun ,&nbsp;Huang Huang ,&nbsp;Haoran Zhuo ,&nbsp;Ranran Qie ,&nbsp;Yuting Xie ,&nbsp;Jiajun Luo ,&nbsp;Ni Li ,&nbsp;Jiang Li ,&nbsp;Jie He ,&nbsp;Briseis Aschebrook-Kilfoy ,&nbsp;Yawei Zhang","doi":"10.1016/j.jncc.2022.09.004","DOIUrl":"10.1016/j.jncc.2022.09.004","url":null,"abstract":"<div><p>Lung cancer is one of the leading causes of cancer incidence and mortality worldwide. While smoking, radon, air pollution, as well as occupational exposure to asbestos, diesel fumes, arsenic, beryllium, cadmium, chromium, nickel, and silica are well-established risk factors, many lung cancer cases cannot be explained by these known risk factors. Over the last two decades the incidence of adenocarcinoma has risen, and it now surpasses squamous cell carcinoma as the most common histologic subtype. This increase warrants new efforts to identify additional risk factors for specific lung cancer subtypes as well as a comprehensive review of current evidence from epidemiologic studies to inform future studies. Given the myriad exposures individuals experience in real-world settings, it is essential to investigate mixture effects from complex exposures and gene-environment interactions in relation to lung cancer and its subtypes.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 216-225"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000667/pdfft?md5=fa6118c1a2ed133f6f2a58f6581b21f7&pid=1-s2.0-S2667005422000667-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48368191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models","authors":"Ergang Wang ,&nbsp;Kun Xiang ,&nbsp;Yun Zhang ,&nbsp;Xiao-Fan Wang","doi":"10.1016/j.jncc.2022.10.001","DOIUrl":"10.1016/j.jncc.2022.10.001","url":null,"abstract":"<div><p>One of the major bottlenecks in advancing basic cancer research and developing novel cancer therapies is the lack of <em>in vitro</em> pre-clinical models that faithfully recapitulate tumor properties in the patients. Monolayer cultures of cancer cell lines usually lose the heterogeneity of the parental tumors, while patient-derived xenograft (PDX) suffers from its time- and resource-intensive nature. The emergence of organoid culture system and its application in cancer research provides a unique opportunity to develop novel <em>in vitro</em> cancer pre-clinical models. Here we review the recent advances in utilizing organoids culture system and other related three-dimensional culture systems in studying cancer biology, performing drug screening, and developing cancer therapies. In particular, we discuss the advantages of applying xenograft initiated from patient-derived organoids (PDOs) as a faithful cancer pre-clinical model in basic cancer research and precision medicine.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 263-276"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000679/pdfft?md5=bb006fd428deb8fd511d5a4d51d3bd15&pid=1-s2.0-S2667005422000679-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46741057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy","authors":"Yunkai Yang ,&nbsp;Min Zhang ,&nbsp;Yan Wang","doi":"10.1016/j.jncc.2022.09.002","DOIUrl":"10.1016/j.jncc.2022.09.002","url":null,"abstract":"<div><p>Histone modifications are key factors in chromatin packaging, and are responsible for gene regulation during cell fate determination and development. Abnormal alterations in histone modifications potentially affect the stability of the genome and disrupt gene expression patterns, leading to many diseases, including cancer. In recent years, mounting evidence has shown that various histone modifications altered by aberrantly expressed modifier enzymes contribute to tumor development and metastasis through the induction of epigenetic, transcriptional, and phenotypic changes. In this review, we will discuss the existing histone modifications, both well-studied and rare ones, and their roles in solid tumors and hematopoietic cancers, to identify the molecular pathways involved and investigate targeted therapeutic drugs to reorganize the chromatin and enhance cancer treatment efficiency. Finally, clinical inhibitors of histone modifications are summarized to better understand the developmental stage of cancer therapy in using these drugs to inhibit the histone modification enzymes.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"2 4","pages":"Pages 277-290"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005422000643/pdfft?md5=6d1a699241fd2615642806ed8be5bb0e&pid=1-s2.0-S2667005422000643-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46305398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}